Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma by Varsha Ananthapadmanabhan, Thomas C. Frost, Kara M. Soroko, Aine Knott, Brianna J. Magliozzi, Prafulla C. Gokhale, Vijaya G. Tirunagaru, Robert C. Doebele, James A. DeCaprio

Get full text

Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model by J. Bryan Iorgulescu, J. Bryan Iorgulescu, J. Bryan Iorgulescu, Neil Ruthen, Ryuhjin Ahn, Ryuhjin Ahn, Eleni Panagioti, Prafulla C. Gokhale, Martha Neagu, Maria C. Speranza, Benjamin K. Eschle, Kara M. Soroko, Raziye Piranlioglu, Meenal Datta, Meenal Datta, Shanmugarajan Krishnan, Kathleen B. Yates, Kathleen B. Yates, Gregory J. Baker, Gregory J. Baker, Rakesh K. Jain, Mario L. Suvà, Mario L. Suvà, Mario L. Suvà, Donna Neuberg, Forest M. White, Forest M. White, E. Antonio Chiocca, Gordon J. Freeman, Arlene H. Sharpe, Arlene H. Sharpe, Arlene H. Sharpe, Catherine J. Wu, Catherine J. Wu, David A. Reardon

Get full text